Master surgery in 5 minutes a day

Get smart summaries of the latest surgical literature delivered daily. 5K+ surgical leaders already rely on Stitches to save time and stay ahead.

100% Free. No spam. Unsubscribe any time.

WHAT READERS SAY

As a consultant, my inbox is flooded with emails. But this one always makes the cut.

Sarah, Consultant (Germany)

The Daily Selection has completely changed my approach to reading surgical literature!

David, Trainee (UK)

An easy way to stay up to date in this fast paced field

N.E., Resident

How do you lead in the OR?
Every surgical team needs a leader — but leadership comes in many forms. Where do you fit in?

Take our quick quiz and discover your surgical leadership style in just 2 minutes.
It’s fun, fast, and scarily accurate.

👉 Want to dig deeper? Read our article on surgical leadership here.

Why STITCHES?

We make reading surgical science enjoyable and informative

SAVE TIME

STITCHES makes it easy by collecting all academic surgical papers and offering them to you in theme-based newsletters.

GET UNIQUE INSIGHTS

STITCHES is made by surgeons for surgeons, and we search every journal for the news and information you are looking for.

ENJOY STAYING INFORMED

We provide a 1) Daily Selection of the top 5 papers summarized daily, or subscribe to our 2) specialty newsletter for ALL articles in that field.

TOP STITCHES

  • Five-Year Survival After Neoadjuvant Therapy for PDAC Is 34.5%
    Actual 5-year survival after neoadjuvant therapy and resection for localized pancreatic ductal adenocarcinoma is 34.5%, with early recurrence as the leading cause of treatment failure. Among 660 patients, recurrence occurred in 74.1%, predominantly within the first year post-surgery. Survival rates were stratified: 42.5% for resectable, 29.0% for borderline-resectable, and 17.5% for locally advanced disease. Key predictors for long-term survival included lower comorbidity, baseline CA19-9 <200 U/mL, and complete R0 resection. Awareness of these survival outcomes and predictors can guide patient… Read more: Five-Year Survival After Neoadjuvant Therapy for PDAC Is 34.5%

Get the Latest in Surgery!